| P2093 | author name string | Erwin Bischoff | |
| | Helmut Haning | |
| | Ulrich Niewöhner | |
| P2860 | cites work | Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase | Q74299411 |
| | Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes | Q74582058 |
| | Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro | Q74607760 |
| | 4-Benzylamino-1-chloro-6-substituted phthalazines: synthesis and inhibitory activity toward phosphodiesterase 5 | Q77158414 |
| | 1-Arylnaphthalene lignan: a novel scaffold for type 5 phosphodiesterase inhibitor | Q77305522 |
| | Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis | Q77620684 |
| | Bosentan therapy for pulmonary arterial hypertension | Q77801473 |
| | Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors | Q77957796 |
| | Functional changes in troponin T by a splice donor site mutation that causes hypertrophic cardiomyopathy | Q78117020 |
| | Synthesis and evaluation of potent and selective c-GMP phosphodiesterase inhibitors | Q78173829 |
| | Sildenafil | Q93949487 |
| | Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase | Q24336601 |
| | Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation | Q24530647 |
| | Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family) | Q28118697 |
| | Cyclic nucleotide phosphodiesterases | Q28203598 |
| | Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds | Q28368113 |
| | Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases | Q28512548 |
| | Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice | Q28594618 |
| | Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles | Q30984096 |
| | 4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5. | Q31406470 |
| | Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum | Q31804299 |
| | Identification and regulation of human PDE5A gene promoter | Q31855585 |
| | Cyclic GMP phosphodiesterase-5: target of sildenafil | Q33630333 |
| | Sildenafil: a review of its use in erectile dysfunction | Q33684280 |
| | Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions | Q33860484 |
| | Erectile dysfunction | Q33942524 |
| | Central neural regulation of penile erection | Q33958452 |
| | Cyclic nucleotide phosphodiesterases: relating structure and function | Q34047795 |
| | Studies on the mechanism of hormone action | Q34052022 |
| | Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation | Q34113265 |
| | The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil | Q34118020 |
| | Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil | Q34118218 |
| | Current management of primary pulmonary hypertension | Q34439267 |
| | Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. | Q34467066 |
| | Sildenafil citrate: lessons learned from 3 years of clinical experience | Q34535526 |
| | IC351 (tadalafil, Cialis): update on clinical experience | Q34535533 |
| | Vardenafil: update on clinical experience | Q34535540 |
| | Pulmonary hypertension in patients with chronic obstructive pulmonary disease: recent advances in pathophysiology and management | Q34565226 |
| | Guanosine 3':5'-cyclic monophosphate binding proteins in rat tissues | Q35015091 |
| | Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice | Q35055811 |
| | Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. | Q35126913 |
| | Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021 | Q70868716 |
| | Synthesis and cyclic GMP phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d]pyrimidones | Q71121693 |
| | Characterization of a novel potent and specific inhibitor of type V phosphodiesterase | Q71598841 |
| | Nitric oxide in the penis: physiology and pathology | Q71927171 |
| | Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities | Q72019114 |
| | Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity | Q72052707 |
| | Cyclic GMP phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline | Q72641392 |
| | Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study | Q72641848 |
| | Characterization and effects of methyl-2- (4-aminophenyl)-1, 2-dihydro-1-oxo-7- (2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (P | Q73011653 |
| | Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle | Q73146055 |
| | Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors | Q73334770 |
| | Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors | Q73376289 |
| | Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity | Q73497051 |
| | William Harvey Research Conference on PDE inhibitors: drugs with an expanding range of therapeutic uses | Q73500663 |
| | N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction | Q73641901 |
| | Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues | Q73685183 |
| | Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction | Q73738783 |
| | Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors | Q74066766 |
| | Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D | Q35801500 |
| | Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function | Q36457086 |
| | Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats | Q37351285 |
| | Cyclic GMP cascade of vision | Q38162557 |
| | Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase | Q38332843 |
| | Molecular properties of the cGMP cascade of vertebrate photoreceptors | Q39508434 |
| | Inhibition of separated forms of phosphodiesterases from pig coronary arteries by uracils and by 7-substituted derivatives of 1-methyl-3-isobutylxanthine | Q39986151 |
| | Physiology of penile erection | Q40576740 |
| | Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission | Q41082098 |
| | Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells | Q41448032 |
| | The influence of medication on erectile function | Q41460510 |
| | Tailoring cAMP-signalling responses through isoform multiplicity | Q41516369 |
| | Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum | Q41719981 |
| | The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways | Q41979311 |
| | Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). cGMP versus cAMP substrate selectivity | Q42060786 |
| | Effects of sildenafil on esophageal motility of normal subjects | Q42513039 |
| | Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor | Q42551892 |
| | Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor | Q42557425 |
| | Defective smooth muscle regulation in cGMP kinase I-deficient mice | Q42645524 |
| | Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine | Q42847426 |
| | Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials | Q43566599 |
| | On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction | Q43583270 |
| | Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum | Q43628332 |
| | Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. | Q43628509 |
| | Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives | Q43639538 |
| | Synthesis and phosphodiesterase 5 inhibitory activity of novel phenyl ring modified sildenafil analogues | Q43641509 |
| | Synthesis and phosphodiesterase 5 inhibitory activity of new 5-phenyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one derivatives containing an N-acylamido group phenyl ring | Q43653194 |
| | The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial | Q43700446 |
| | A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection | Q43700460 |
| | The discovery of novel, potent and selective PDE5 inhibitors | Q43732228 |
| | Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension | Q43733941 |
| | Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder | Q43735469 |
| | Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogues containing a carboxylic acid group in the 5'-sulfonamide moiety of a phenyl ring | Q43764217 |
| | Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus | Q43787678 |
| | Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells | Q43809044 |
| | cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation | Q43880286 |
| | Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. | Q43942580 |
| | Animal models of human retinal dystrophies | Q45889604 |
| | Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. | Q46032266 |
| | Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs | Q46668473 |
| | New inhibitor of reagin-mediated anaphylaxis | Q46726841 |
| | Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans | Q46826426 |
| | Phosphodiesterase inhibitors in the treatment of erectile dysfunction | Q47739017 |
| | Cardiovascular activity of WIN 65579, a novel inhibitor of cyclic GMP phosphodiesterase 5. | Q47816035 |
| | 8-(4-Chlorophenyl)thio-cyclic AMP is a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA) | Q52408106 |
| | Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. | Q53348475 |
| | Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction | Q56067856 |
| | Strategic approaches to drug design. II. Modelling studies on phosphodiesterase substrates and inhibitors | Q69843559 |
| | Isolation of cyclic nucleotide phosphodiesterase isozymes from pig aorta | Q70475523 |
| | Hemodynamics of canine corpora cavernosa during erection | Q70633373 |
| P304 | page(s) | 249-306 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Progress in medicinal chemistry | Q27712806 |
| P1476 | title | Phosphodiesterase type 5 (PDE5) inhibitors | |
| P478 | volume | 41 | |